Methods and compositions for enhancing nuclease-mediated gene disruption

Patent metadata

Field	Value
Publication number	US-10227610-B2
Application number	US-201414188212-A
Country	US
Kind code	B2
Filing date	Feb 24, 2014
Priority date	Feb 25, 2013
Publication date	Mar 12, 2019
Grant date	Mar 12, 2019

Abstract

Methods and compositions for increasing nuclease-mediated genomic modification using DNA repair inhibitors are provided.

First claim

What is claimed is:

1. A method for targeted genomic disruption via microhomology-mediated end joining (MMEJ) in a cell, the method comprising:
administering at least one nuclease to the cell, wherein the nuclease cleaves endogenous genomic sequences in the cell, wherein the nuclease is a zinc finger nuclease, a TALE effector domain nuclease (TALEN) and/or a CRISPR/Cas nuclease system; and
growing the cell in a medium comprising at least one small molecule inhibitor of a DNA-dependent-protein kinase catalytic subunit (DNA-PKcs) protein and a small molecule inhibitor of a Poly-(ADP-ribose) polymerase 1/2 (PARP1/2) protein at 0.5 to 25 wherein the small molecule inhibitor is a nicotinamide; a isoquinolinone and a dihydroisoquinolinones; a benzimidazole; an indole; phthalazin-1(2H)-one; a quinazolinone; an isoindolinone and analogues and derivatives thereof; a phenanthridine; a phenanthridinone; a benzopyrone and analogues and derivatives thereof; an unsaturated hydroximic acid derivative and analogues and derivatives thereof; a pyridazine; caffeine, theophylline; thymidine and/or NU7026 and/or NU7441, wherein the endogenous genomic sequences in the cell are disrupted via MMEJ after cleavage by the at least one nuclease.

2. The method of claim 1 , wherein the DNA-PKcs protein and/or (PARP1/2) protein is selected from the group consisting of PARP1, Ku70/80, DNA-PKcs, XRCC4/XLF, Ligase IV, Ligase III, XRCC1, Artemis Polynucleotide Kinase (PNK) and combinations thereof.

3. The method of claim 1 , wherein the targeted genomic disruption comprises a deletion.

4. The method of claim 1 , wherein the targeted genomic disruption comprises an insertion.

5. The method of claim 4 , further comprising administering an exogenous sequence to the cell, wherein the exogenous sequence is integrated into the genome via homology directed repair (HDR) mechanisms following cleavage by the nuclease.

6. The method of claim 5 , wherein the exogenous sequence is selected from the group consisting of a sequence encoding a protein, a regulatory sequence, a sequence that encodes a structural RNA and combinations thereof.

7. The method of claim 1 , wherein the nuclease is administered using an expression vector or as mRNA.

8. The method of claim 1 , wherein the cell further comprises a Rad52 mRNA.

Assignees

• Sangamo Therapeutics Inc
• Sigma Aldrich Co Llc

Inventors

• Chen Fuqiang
• Kang Qiaohua
• Wechsler Thomas

Classifications

• A61P43/00

  Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00 · CPC title

• A61K31/502

  ortho- or peri-condensed with carbocyclic ring systems, e.g. cinnoline, phthalazine · CPC title

• C07K2319/81

  containing a Zn-finger domain for DNA binding · CPC title

• C07K2319/80

  containing a DNA binding domain, e.g. Lacl or Tet-repressor · CPC title

• C12N15/907 Primary

  in mammalian cells · CPC title